An experimental proton magnetic resonance spectroscopy analysis on early stage of acute focal cerebral ischemia

2002 ◽  
Vol 22 (4) ◽  
pp. 359-361
Author(s):  
Li Yi ◽  
Suming Zhang ◽  
Xinjiang Zhang
Keyword(s):  
Cerebral Ischemia ◽  
Magnetic Resonance ◽  
Magnetic Resonance Spectroscopy ◽  
Proton Magnetic Resonance ◽  
Proton Magnetic Resonance Spectroscopy ◽  
Focal Cerebral Ischemia ◽  
Early Stage ◽  
Resonance Spectroscopy ◽  
Spectroscopy Analysis

scholarly journals Expanded neurochemical profile in the early stage of Huntington disease using proton magnetic resonance spectroscopy

2018 ◽  
Vol 31 (3) ◽  
pp. e3880 ◽  
Author(s):  
Isaac M. Adanyeguh ◽  
Marie-Lorraine Monin ◽  
Daisy Rinaldi ◽  
Léorah Freeman ◽  
Alexandra Durr ◽  
...  
Keyword(s):  
Magnetic Resonance ◽  
Magnetic Resonance Spectroscopy ◽  
Huntington Disease ◽  
Proton Magnetic Resonance ◽  
Proton Magnetic Resonance Spectroscopy ◽  
Early Stage ◽  
Resonance Spectroscopy ◽  
Neurochemical Profile

Functional and metabolic analysis of cerebral ischemia using magnetoencephalography and proton magnetic resonance spectroscopy

1997 ◽  
Vol 42 (4) ◽  
pp. 554-563 ◽  
Author(s):  
Kyousuke Kamada ◽  
Mark Saguer ◽  
Martin Möller ◽  
Karsten Wicklow ◽  
Martin Katenhäuser ◽  
...  
Keyword(s):  
Cerebral Ischemia ◽  
Magnetic Resonance ◽  
Magnetic Resonance Spectroscopy ◽  
Proton Magnetic Resonance ◽  
Proton Magnetic Resonance Spectroscopy ◽  
Resonance Spectroscopy ◽  
Metabolic Analysis

Hippocampal neurochemical markers in bipolar disorder patients following the first-manic episode: A prospective 12-month proton magnetic resonance spectroscopy study

2016 ◽  
Vol 51 (1) ◽  
pp. 65-74 ◽  
Author(s):  
Leonardo E Silveira ◽  
David J Bond ◽  
Erin Leigh MacMillan ◽  
Jan-Marie Kozicky ◽  
Kesavan Muralidharan ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Magnetic Resonance ◽  
Magnetic Resonance Spectroscopy ◽  
Healthy Subjects ◽  
Proton Magnetic Resonance ◽  
Proton Magnetic Resonance Spectroscopy ◽  
Early Stage ◽  
Manic Episode ◽  
Resonance Spectroscopy ◽  
Mood Episode

Objective: Previous studies reported decreased N-acetyl aspartate and increased Glx (the sum of glutamate plus glutamine) in bipolar disorder. Since these studies included patients at different stages of illness, it is unknown whether these changes have a causal role or a consequence of multiple episodes and treatments. The studies in early-stage bipolar disorder patients have the potential to provide answers to these issues. Therefore, we evaluated N-acetyl aspartate and Glx levels in hippocampi of first-episode bipolar disorder patients and health subjects at baseline and at 12 months, and examined the impact of episode recurrence on these measures. Method: We used single-voxel proton magnetic resonance spectroscopy to compare the hippocampal neurometabolites ( N-acetyl aspartate and Glx) levels between 41 patients with bipolar disorder following recovery from their first-manic episode and 27 matched healthy subjects at recruitment and 12 months later. We also compared N-acetyl aspartate and Glx levels between patients who had a recurrence of a mood episode and those who did not. Results: There was no main effect of either group (diagnosis) or time for hippocampal N-acetyl aspartate and Glx levels in bipolar disorder patients and healthy subjects. We also did not find any group-by-time interaction for the levels of these metabolites. There were also no differences in N-acetyl aspartate and Glx between patients who experienced a recurrence of a mood episode and those who did not over 12-month follow-up. Conclusion: Our data suggest that N-acetyl aspartate and Glx levels are not altered in early stage bipolar disorder. Further, these data suggest that episode recurrence in early stages does not have a significant impact on the levels of these metabolites. These may suggest that there may be an early window for intervention to potentially arrest neuroprogression of the disease.

scholarly journals Clinical Application of Proton Magnetic Resonance Spectroscopy to Cerebral Ischemia

1991 ◽  
Vol 31 (7) ◽  
pp. 385-389 ◽  
Author(s):  
Kiyohiro HOUKIN ◽  
Hitoshi MATSUZAWA ◽  
Mikio NOMURA ◽  
Hisatoshi SAITOH ◽  
Hiroyasu KAMIYAMA ◽  
...  
Keyword(s):  
Cerebral Ischemia ◽  
Magnetic Resonance ◽  
Magnetic Resonance Spectroscopy ◽  
Clinical Application ◽  
Proton Magnetic Resonance ◽  
Proton Magnetic Resonance Spectroscopy ◽  
Resonance Spectroscopy

scholarly journals Imaging intelligence with proton magnetic resonance spectroscopy

Intelligence ◽  
2009 ◽  
Vol 37 (2) ◽  
pp. 192-198 ◽  
Author(s):  
Rex E. Jung ◽  
Charles Gasparovic ◽  
Robert S. Chavez ◽  
Arvind Caprihan ◽  
Ranee Barrow ◽  
...  
Keyword(s):  
Magnetic Resonance ◽  
Magnetic Resonance Spectroscopy ◽  
Proton Magnetic Resonance ◽  
Proton Magnetic Resonance Spectroscopy ◽  
Resonance Spectroscopy

Disulfiram Determination by Proton Magnetic Resonance Spectroscopy and by Colorimetry

1973 ◽  
Vol 56 (1) ◽  
pp. 124-127 ◽  
Author(s):  
Eric B Sheinin ◽  
Walter R Benson ◽  
Myron M Smith
Keyword(s):  
Magnetic Resonance ◽  
Magnetic Resonance Spectroscopy ◽  
Proton Magnetic Resonance ◽  
Proton Magnetic Resonance Spectroscopy ◽  
Colorimetric Method ◽  
Drug Substance ◽  
Resonance Spectroscopy ◽  
Pmr Spectroscopy ◽  
Label Claim ◽  
Tablet Excipients

Abstract Disulfiram was determined in disulfiram drug substance and tablets by proton magnetic resonance (PMR) spectroscopy at the 100–480 mg level and by a colorimetric technique involving cuprous iodide at the 50 mg level. The tablet excipients do not interfere in the analysis. The average result for disulfiram in a tablet composite was 100.8±1.4% of label claim by PMR and 100.7±0.4% by the colorimetric method.

Sign in / Sign up

Export Citation Format

Share Document